Related Experiment Video
Updated: Jun 7, 2025
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Lessons Learned From Clinical Trials of Immunotherapeutics for COVID-19
Inyeong Lee1, Christopher R Lupfer2
1R&D Department, QoolAbs, Carlsbad, California, USA.
Abstract:
The COVID-19 pandemic caused by the SARS-CoV-2 virus was arguably one of the worst public health disasters of the last 100 years. As many infectious disease experts were focused on influenza, MERS, ZIKA, or Ebola as potential pandemic-causing agents, SARS-CoV-2 appeared to come from nowhere and spread rapidly. As with any zoonotic agent, the initial pathogen was able to transmit to a new host (humans), but it was poorly adapted to the immune environment of the new host and resulted in a maladapted immune response. As the host-pathogen interaction evolved, subsequent variants of SARS-CoV-2 became less pathogenic and acquired immunity in the host provided protection, at least partial protection, to new variants. As the host-pathogen interaction has changed since the beginning of the pandemic, it is possible the clinical results discussed here may not be applicable today as they were at the start of the pandemic. With this caveat in mind, we present an overview of the immune response of severe COVID-19 from a clinical research perspective and examine clinical trials utilizing immunomodulating agents to further elucidate the importance of hyperinflammation as a factor contributing to severe COVID-19 disease.
Insights
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic led to a maladapted immune response in humans. This study examines the immune response in severe COVID-19 and the role of hyperinflammation.
Area of Science:
- Immunology
- Virology
- Public Health
Background:
- The COVID-19 pandemic, caused by SARS-CoV-2, emerged rapidly, overwhelming global health systems.
- Initial SARS-CoV-2 strains were poorly adapted to the human immune system, causing severe disease.
- Host-pathogen interactions and viral evolution have altered disease presentation and severity over time.
Purpose of the Study:
- To provide an overview of the immune response in severe COVID-19 from a clinical research perspective.
- To examine clinical trials of immunomodulating agents in COVID-19.
- To elucidate the role of hyperinflammation in severe COVID-19.
Main Methods:
- Review of clinical research on severe COVID-19 immune responses.
- Analysis of clinical trials involving immunomodulating agents.
- Examination of host-pathogen interactions and viral evolution.
Main Results:
- Severe COVID-19 is characterized by a maladapted immune response to SARS-CoV-2.
- Hyperinflammation is a significant factor contributing to severe COVID-19 disease.
- Immunomodulating agents are being investigated to manage severe COVID-19.
Conclusions:
- Understanding the evolving immune response to SARS-CoV-2 is crucial.
- Hyperinflammation plays a key role in severe COVID-19 pathogenesis.
- Clinical research on immunomodulation offers potential therapeutic strategies.
Related Concept Videos
01:27Tumor Immunotherapy
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:29Microorganisms in Medicine and Therapeutics
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:51Vaccinations